Company intelligence / Profile preview

Madera Pharmaceuticals

Las Vegas, Nevada, United Statesmaderapharmaceuticals.com ↗

Ownership: Private
Development stage: Other

Overview

Madera Pharmaceuticals is developing a patented transdermal drug delivery platform. Its lead program is a fast-acting topical formulation of alprostadil targeting erectile dysfunction. Animal efficacy and skin permeation studies are complete; human trials are expected in 2025. The company plans to commercialize via compounding pharmacies by 2026 and pursue FDA approval through the streamlined 505(b)(2) pathway.

Therapeutic areas: Women's HealthMen's HealthEndocrinologyCardiovascular
Modalities: Small moleculeBiologic (via transdermal delivery platform for drugs like alprostadil)
Industry: Biotech

Drug pipeline

1 asset

Madera topical alprostadil

Pre-clinical

Indications: Erectile dysfunction, Female sexual dysfunction, Alopecia, Raynaud's syndrome, Arthritis

Partnerships

Not disclosed as of June 2025.

Beyond the preview

Go deeper on Madera Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Madera Pharmaceuticals.

Explore the full profile